データなし
データなし
Omeros Corp (OMER): Profit-Taking Time Amid ASH Presentations and Financial Challenges
Omeros Corporation Presents Phase 2 Zaltenibart Data At ASH Meeting, Supporting Dose Selection For Upcoming Phase 3 Clinical Trials In Paroxysmal Nocturnal Hemoglobinuria, With Enrollment Set For Early 2025
AppLovin, MicroStrategy, and 28 Other Stocks That Could Be Bubbles
Jim Cramer Prefers FedEx Over This Delivery Giant That 'Screwed Up A Lot Of Holiday Seasons'
Replimune REPL +35% BLA Submission; Omeros OMER +41% BLA Update
Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday